Inhibition of factor IXa by the pegnivacogin system during cardiopulmonary bypass: a potential substitute for heparin. A study in baboons | Zendy

Alain Bel | Zendy; Wasseem Borik | Zendy; Simon Davidson | Zendy; JeanMarie Héliès | Zendy; Lev Stimmer | Zendy; Stephen E. Fremes | Zendy; Steven L. Zelenkofske | Zendy; Christopher Rusconi | Zendy; John H. Alexander | Zendy; David N. Alexander | Zendy; Philippe Menasché | Zendy; John Pepper | Zendy

Open Access

Inhibition of factor IXa by the pegnivacogin system during cardiopulmonary bypass: a potential substitute for heparin. A study in baboons

Author(s) -

Alain Bel,

Wasseem Borik,

Simon Davidson,

JeanMarie Héliès,

Lev Stimmer,

Stephen E. Fremes,

Steven L. Zelenkofske,

Christopher Rusconi,

John H. Alexander,

David N. Alexander,

Philippe Menasché,

John Pepper

Publication year - 2015

Publication title -

european journal of cardio-thoracic surgery

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.303

H-Index - 133

eISSN - 1873-734X

pISSN - 1010-7940

DOI - 10.1093/ejcts/ezv159

Subject(s) - cardiopulmonary bypass , protamine , heparin , activated clotting time , factor ixa , baboon , medicine , anesthesia , coagulation , anticoagulant , pharmacology , thrombin , cardiology , platelet , factor x

Heparin and protamine are standard for anticoagulation and reversal for cardiopulmonary bypass (CPB). The REGADO biosciences protocol 1 (REG1) anticoagulant system, consisting of the Factor IXa (FIXa)-inhibitor pegnivacogin and its reversal agent (anivamersen), has been studied in patients undergoing coronary catheterization and in CPB in sheep and pigs. Prior to first human use in CPB, we wanted to test the safety and efficacy of REG1 in a primate model.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research